MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata”; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its ...
TOKYO and MASSACHUSETTS, Nov. 9, 2015 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc ...
After months of agitating and activism from miffed shareholders, Astellas has finally convinced the majority of Ocata Therapeutics investors to accept its $8.50-a-share offer, ending a surprisingly ...
Executives struck a triumphant tone last month when Ocata Therapeutics Inc., of Marlborough, said it had agreed to be sold to the Japanese drug maker Astellas Pharma Inc., in a $379 million deal that ...
Ocata Therapeutics of Marlborough has been awarded a federal grant to help pay for further preclinical development of a potential treatment for two forms of lupus, representing a new potential product ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that data will be ...
Paul K. Wotton, center, and employees of Ocata Therapeutics of Marlborough, participated in the opening bell ceremony at the NASDAQ Marketsite in New York City. The company will no longer be listed as ...
Robert Lanza, one of the most prominent scientists in the field of stem cell biology, on Monday said he will lead global regenerative medicine research at Astellas Pharma Inc., the Japanese drug maker ...
The acquisition of Ocata represents the coming together of two companies with significant accomplishments and a shared commitment to development innovative therapies that address the unmet medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results